Urology and Renal Transplantation Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Bonomo Teaching Hospital, Andria (BAT), Italy.
J Transl Med. 2021 Jan 6;19(1):24. doi: 10.1186/s12967-020-02684-3.
Benign prostatic hyperplasia (BPH) is the most common urologic disease among elderly men. The diagnosis of BPH is usually driven by lower urinary tract symptoms (LUTS) that can significantly affect patients' quality of life. This phase II prospective, randomized double-blinded, placebo-controlled study aimed to determine the efficacy and safety of a novel whole tomato-based food supplement on LUTS of patients diagnosed with BPH.
Forty consecutive patients with histologically proved BPH were randomized 1:1 to receive daily for 2 months a sachet (5 g) of a newly developed whole tomato food supplement (WTFS) (treatment = Group A) or placebo (Group B). Patients were asked to fill the International Prostatic Symptom Score (IPSS) questionnaire before and after treatment.
All but 1 patient in Group B successfully completed the scheduled regimen. No side effects were recorded. Unlike placebo, treatment significantly reduced (P < 0.0002) LUTS since mean IPSS decreased from 9.05 ± 1.15 to 7.15 ± 1.04 (paired t-test, two-tailed P-value < 0.001), and improved life quality (P < 0.0001). A trend toward a reduction of total PSA levels was observed in WTFS treated patients (8.98 ng/mL ± 1.52 vs 6.95 ± 0.76, P = 0.065), with changes being statistically significant only in the subgroup of patients with baseline levels above 10 ng/mL (18.5 ng/mL ± 2.7 vs 10.3 ± 2.1, P = 0.009).
The new WTFS may represent a valid option for the treatment of symptomatic BPH patients. Unlike pharmacological treatments, the supplement is side effects free and highly accepted among patients.
良性前列腺增生(BPH)是老年男性中最常见的泌尿科疾病。BPH 的诊断通常由下尿路症状(LUTS)驱动,这些症状会严重影响患者的生活质量。本 II 期前瞻性、随机、双盲、安慰剂对照研究旨在确定一种新型全番茄基食品补充剂对 BPH 患者 LUTS 的疗效和安全性。
连续 40 例经组织学证实的 BPH 患者随机 1:1 接受 2 个月的每日治疗,分别接受 1 个新开发的全番茄食品补充剂(WTFS)小袋(5 克)(治疗组=A 组)或安慰剂(B 组)。治疗前后患者均需填写国际前列腺症状评分(IPSS)问卷。
B 组除 1 例患者外,其余患者均成功完成了预定疗程。未记录到任何副作用。与安慰剂组相比,治疗组显著降低了 LUTS(P<0.0002),因为平均 IPSS 从 9.05±1.15 降至 7.15±1.04(配对 t 检验,双侧 P 值<0.001),并且改善了生活质量(P<0.0001)。WTFS 治疗患者的总 PSA 水平呈下降趋势(8.98ng/mL±1.52 对 6.95ng/mL±0.76,P=0.065),仅在基线水平高于 10ng/mL 的亚组中变化具有统计学意义(18.5ng/mL±2.7 对 10.3ng/mL±2.1,P=0.009)。
新型 WTFS 可能是治疗有症状的 BPH 患者的有效选择。与药物治疗不同,该补充剂无副作用,并且在患者中高度接受。